denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Hematology Disease Topics & Pathways:
Biological therapies, Viral, Clinical Practice (Health Services and Quality), Bacterial, Lymphomas, non-Hodgkin lymphoma, genomics, B Cell lymphoma, Diseases, indolent lymphoma, Therapies, Infectious Diseases, Lymphoid Malignancies, Biological Processes, pathogenesis
Hematology Disease Topics & Pathways:
Biological therapies, Viral, Clinical Practice (Health Services and Quality), Bacterial, Lymphomas, non-Hodgkin lymphoma, genomics, B Cell lymphoma, Diseases, indolent lymphoma, Therapies, Infectious Diseases, Lymphoid Malignancies, Biological Processes, pathogenesis
Sunday, December 11, 2022: 4:30 PM-5:45 PM
Great Hall BC
(Ernest N. Morial Convention Center)
Description:
Session is designed to expire the biopsy of low grade lymphoma and link how this has lead to the introduction of several new agents in the management of patients. Dr. Jessica Okosun will discuss the pathogenesis of follicular lymphoma and how this has lead to development of several novel agents. Dr. Luca Arcaini will discuss options for patients with marginal zone lymphoma and its varied subtypes.
Chair:
Tycel J. Phillips, MD, City of Hope
Disclosures:
Phillips: Abbvie: Consultancy; Astra Zeneca: Consultancy; Beigene: Consultancy; BMS: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Bayer: Consultancy, Research Funding; Genmab: Consultancy; Genentech: Consultancy, Research Funding; Gilead: Consultancy; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; Eli Lily: Consultancy; Pharmacyclics: Consultancy; Incyte: Consultancy.
Session is designed to expire the biopsy of low grade lymphoma and link how this has lead to the introduction of several new agents in the management of patients. Dr. Jessica Okosun will discuss the pathogenesis of follicular lymphoma and how this has lead to development of several novel agents. Dr. Luca Arcaini will discuss options for patients with marginal zone lymphoma and its varied subtypes.
See more of: Education Program